Author

Davide Giuseppe Ribaldone

PREVALENCE AND RISK FACTOR OF PERIODONTITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A CASE-CONTROL, PROSPECTIVE STUDY
PREVALENCE AND RISK FACTOR OF PERIODONTITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A CASE-CONTROL, PROSPECTIVE STUDY

NEW ONSET OF IBD IN A PATIENT AFFECTED BY SEVERE PSORIASIS: A CASE OF SECONDARY FAILURE TO USTEKINUMAB SUCCESSFULLY TREATED WITH RISANKIZUMAB
NEW ONSET OF IBD IN A PATIENT AFFECTED BY SEVERE PSORIASIS: A CASE OF SECONDARY FAILURE TO USTEKINUMAB SUCCESSFULLY TREATED WITH RISANKIZUMAB

CELIAC DISEASE AMONG A LARGE INFLAMMATORY BOWEL DISEASE POPOULATION: EPIDEMIOLOGY AND OUTCOME
CELIAC DISEASE AMONG A LARGE INFLAMMATORY BOWEL DISEASE POPOULATION: EPIDEMIOLOGY AND OUTCOME

Davide Giuseppe Ribaldone  et al.

MULTIPLE SCLEROSIS PREVALENCE IN HIGHER IN CROHN’S DISEASE PATIENTS THAN IN GENERAL POPULATION, BUT DOES NOT INFLUENCE INFLAMMATORY BOWEL DISEASE OUTCOME
MULTIPLE SCLEROSIS PREVALENCE IN HIGHER IN CROHN’S DISEASE PATIENTS THAN IN GENERAL POPULATION, BUT DOES NOT INFLUENCE INFLAMMATORY BOWEL DISEASE OUTCOME

Davide Giuseppe Ribaldone  et al.

NEW ONSET OF IBD IN A PATIENT AFFECTED BY SEVERE PSORIASIS: A CASE OF SECONDARY FAILURE TO USTEKINUMAB SUCCESSFULLY TREATED WITH RISANKIZUMAB
NEW ONSET OF IBD IN A PATIENT AFFECTED BY SEVERE PSORIASIS: A CASE OF SECONDARY FAILURE TO USTEKINUMAB SUCCESSFULLY TREATED WITH RISANKIZUMAB

Davide Giuseppe Ribaldone  et al.

EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY
EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY

Davide Giuseppe Ribaldone  et al.

PREVALENCE AND RISK FACTOR OF PERIODONTITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A CASE-CONTROL, PROSPECTIVE STUDY
PREVALENCE AND RISK FACTOR OF PERIODONTITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A CASE-CONTROL, PROSPECTIVE STUDY

Davide Giuseppe Ribaldone  et al.

DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE
DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE

Davide Giuseppe Ribaldone  et al.

BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS
BIOLOGIC AGENTS IN IBD PATIENTS AFTER SOLID ORGAN TRANSPLANTATION DO NOT INCREASE THE RATES OF INFECTION OR ADVERSE EVENTS

Davide Giuseppe Ribaldone  et al.

USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY
USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY

Davide Giuseppe Ribaldone  et al.

Item 1 - 10 / 10
1